Open AccessImportant Interactions of Immunosuppressants With Experimental Therapies for Novel Coronavirus Disease (COVID-19): How to Act
Author(s) -
Tanja R Zijp,
Martha L Toren-Wielema,
Prashant V Nannan Panday,
Jos G. W. Kosterink,
Stefan P. Berger,
Daan Touw
Publication year - 2020
Publication title -
therapeutic drug monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.649
H-Index - 93
eISSN - 1536-3694
pISSN - 0163-4356
DOI - 10.1097/ftd.0000000000000766
Subject(s) - ritonavir , lopinavir , medicine , lopinavir/ritonavir , tacrolimus , pharmacology , drug , dosing , hydroxychloroquine , cyp3a , chloroquine , clinical trial , drug interaction , disease , immunology , covid-19 , transplantation , infectious disease (medical specialty) , viral load , human immunodeficiency virus (hiv) , cytochrome p450 , malaria , metabolism , antiretroviral therapy